Needle-Free Drug Delivery Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Needle-Free Drug Delivery Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The needle-free drug delivery devices market is expected to register a CAGR of 6.5% over the forecast period.

The COVID-19 outbreak greatly impacted every aspect of the medical device industry, including the needle-free drug delivery devices market. At the outbreak of the COVID-19 pandemic, most pharmaceutical companies and governments worked toward offering efficient medical treatment to COVID-19 patients, and needle-free drug delivery devices were expected to play a vital role in that context as these devices were used in the administration of drugs and vaccines. For instance, in July 2022, research was conducted by the University of Queensland in partnership with Vaxxas, testing the Hexapro SARS-CoV-2 spike vaccine using the Vaxxas high-density microarray patch (HD-MAP) technology, and the results showed that the patch was far more effective at neutralizing COVID-19 variants. Such device advancements in the administration of COVID-19 vaccines will have a positive impact on the market growth rate over the coming years.

Needle-free injection systems are novel ways to introduce various medicines to patients without piercing the skin with a conventional needle. The needle-free drug delivery devices market is being driven by factors such as the rising prevalence of chronic diseases and lifestyle disorders, and the inclination of the population towards self-administration of drugs. Over the last decade, there has been a rise in the prevalence of several chronic diseases, which in several cases require long hospital stays. Some of the major chronic diseases include cancer, kidney failure, and heart disease, among others. Lifestyle diseases, like hypertension, diabetes mellitus, dyslipidemia, and overweight/obesity, are also becoming major risk factors. For instance, according to GLOBOCAN, in 2020, about 19.3 million new cancer cases were reported worldwide, and this number is expected to reach 30.2 million new cases in the year 2040. This shows a gradual rise in the prevalence of cancer over the forecast period, which is expected to increase demand for needle-free drug delivery devices due to their ease of usage and convenient-administration of drugs. Thus, the increasing patient pool and the increasing prevalence of chronic diseases are anticipated to boost the demand for the market studied.

However, the stringent regulatory framework and limitations associated with the use of micro-needle patches are the few factors restraining the growth of the needle-free drug delivery devices market globally.

Key Market TrendsInsulin Delivery Segment is Expected to Witness Good Growth in Application Segment Over the Forecast Period

The insulin delivery segment is expected to witness significant growth over the forecast period owing to factors such as increasing cases of diabetes and increasing adoption of technologically advanced products.

Diabetes, being a chronic disorder, is a major health concern across the world. For instance, as per the International Diabetes Federation (IDF) Diabetes Atlas 2021, the age-adjusted comparative prevalence of diabetes globally for 2021, 2030, and 2045 is estimated as 9.8%, 10.8%, and 11.2%, respectively. The demand for need-free insulin delivery devices is expected to increase with the upsurge in the diabetic population and the advantages offered by these devices over other conventional insulin delivery systems such as pens, pumps, and needles. Insulin delivery is typically done via self-administration devices, owing to which the risk associated with the pain and improper drug delivery using sharp objects or needles is high. Needle-free drug delivery devices, on the other hand, are safe and pain-free solutions and can be automated for regular intervals of time. Hence, these advantages offered by the devices are likely to bolster the demand for insulin delivery among the patient population, in turn boosting the market segment’s growth.

Furthermore, company developments with respect to needle-free drug delivery will help in segment expansion. For instance, in June 2022, Transdermal Specialties Global completed a phase 3 clinical trial of a patented transdermal patch using the U-StripTM transdermal insulin delivery system.

Thus, the increasing prevalence of diabetes and the technological advancements in needle-free drug delivery devices are expected to drive the overall growth of the insulin delivery application segment over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

The major factors driving the growth of needle-free drug delivery systems in North America are the high awareness among the patient population regarding the availability of novel products available in the market as well as the increasing research and development by the major market players. In addition, the higher prevalence of chronic diseases in the region is expected to have a positive impact on the adoption of needle-free drug delivery devices among the patient population. According to the Alzheimer’s Association, Alzheimer’s Disease Facts and Figures 2022, it is estimated that 6.5 million Americans age 65 and older are living with Alzheimer’s dementia in 2022. Also, according to the National Alliance on Mental Illness report 2020, it is estimated that 1.5 million people annually in the United States are affected by schizophrenia. Both Alzheimer’s and schizophrenia treatments involve the use of multiple drug delivery devices for effective drug administration. Thus, the significant prevalence of the diseases will in turn spur the demand for needle-free devices among the patient population.

Furthermore, strategic developments by key market players will augment the growth of the regional market to a great extent. For instance, in March 2022, Corium, Inc. received approval from the United States Food and Drug Administration (FDA) for ADLARITY (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia of the Alzheimer's type.

Likewise, in June 2022, NovaXS Biotech, based in the United States, revealed the new prototype for its needle-free injection therapy smart medical device. Telosis, a patent-pending technology from the company, delivers a narrow stream of medication without a needle in 0.3 seconds and evaluates injection data to enable wiser medical choices. The company claimed that its technology offered a simple and painless substitute for at-home medicine delivery, serving as the first remote medication and self-administration monitoring platform. IVF procedures are considered the first indication of NovaXS.

Thus, owing to the above-mentioned factors, the studied market in the North American region is expected to register significant growth over the forecast period.

Competitive Landscape

The needle-free drug delivery devices market is moderately competitive. The market is currently dominated by innovative companies that are coming up with novel products through the use of technology that reduces the use of needles for drug administration. Some of the companies that currently have a considerable share in the market are Halozyme, Inc. (Antares Pharma.), INJEX Pharma GmbH, 3M, PharmaJet, Mika Medical Co., MannKind Corporation, PenJet, Crossject, Ferring B.V., and Akra Dermojet, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.